Optimizing Neurocognition With Whole Brain Radiation Therapy (WBRT) Using Upfront Pulsed Reduced Dose-Rate (PRDR) Technique (NCT05045950)
Optimizing Neurocognition With Whole Brain Radiation Therapy (WBRT) Using Upfront Pulsed Reduced Dose-Rate (PRDR) Technique (ONCO-RT) - A Phase II Trial of Upfront Pulsed Reduced Dose Rate Whole-Brain Radiation Therapy for Brain Metastases
🩺 Plain-English Summary (8th-Grade Level)
Study patients will receive Whole-brain radiation therapy (WBRT) - pulsed reduced dose rate (PRDR) within 14 days of registration. All patients will receive single daily fractions using 3D conformal radiotherapy. A dose of 30 Gy in 10 fractions will be delivered using the PRDR technique.
Who can join: Review the eligibility criteria below.
Location: Froedtert Hospital & the Medical College of Wisconsin — Milwaukee, Wisconsin
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (2 Sites)
- Froedtert Hospital & the Medical College of Wisconsin — Milwaukee, Wisconsin
- Clement J. Zablocki Veterans Affairs Medical Center — Milwaukee, Wisconsin
📞 Contact the Study Coordinator
Phone: (866) 680-0505
Email: cccto@mcw.edu
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Brain Metastases
- Preop fSRS for Resectable Brain Metastases — Tampa, Florida
- Neurocognitive Functioning With Genu-Sparing Whole Brain Radiation Therapy for Brain Metastases — Washington D.C., District of Columbia
- Study Assessing QBS72S For Treating Brain Metastases — Palo Alto, California
- A Pilot Study to Assess the Clinical Utility of 18F-Fluciclovine (Axumin) PET-CT for Detecting True-versus Pseudo-Progression of Brain Metastases on Immunotherapy — Houston, Texas
- Neurocognitive Decline in Patients With Brain Metastases — Dallas, Texas
- MRI Following Stereotactic Radiosurgery (SRS) for Brain Metastases — Durham, North Carolina
Explore by condition: All Brain Metastases clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.